Syntheses of Platinum–Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs

Platinum(II)–sulindac complexes [{η2-C5H4SN(O)}Pt(DMSO){O(C=O)Sulindac}], [{η2-C5H4SN(O)}PtCl{(S=O)Sulindac}], [{η2-C5H4SN(O)}PtCl{(S=O)Sulindac–succinimide}], and [{η2-C5H4SN(O)}PtCl{(S=O)Sulindac–thymidine}] were synthesized that exhibited IC50 values of 2.9–4.8 μm against human oral cancer cells OECM1. The poly(lactic-co-glycolic acid) (PLGA) encapsulated [{η2-C5H4SN(O)}PtCl{(S=O)Sulindac}] also showed cytotoxic activity although less potent than the pristine species.